Premium
Prevention of Ventricular Fibrillation by Cilostazol, an Oral Phosphodiesterase Inhibitor, in a Patient with Brugada Syndrome
Author(s) -
TSUCHIYA TAKESHI,
ASHIKAGA KEIICHI,
HONDA TOSHIHIRO,
ARITA MAKOTO
Publication year - 2002
Publication title -
journal of cardiovascular electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.193
H-Index - 138
eISSN - 1540-8167
pISSN - 1045-3873
DOI - 10.1046/j.1540-8167.2002.00698.x
Subject(s) - medicine , cilostazol , brugada syndrome , ventricular fibrillation , discontinuation , cardiology , phosphodiesterase inhibitor , proarrhythmia , drug , phosphodiesterase , atrial fibrillation , anesthesia , pharmacology , aspirin , biochemistry , chemistry , enzyme
Cilostazol and Brugada Syndrome. We report the case of 67‐year‐old man with Brugada syndrome, in whom daily episodes of ventricular fibrillation (VF) occurred every early morning for 4 days. The episodes of VF were completely prevented by an oral administration of cilostazol, a phosphodiesterase inhibitor. This effect was confirmed by the on‐and‐off challenge test, in which discontinuation of the drug resulted in recurrence of VF and resumption of the drug again prevented VF. This effect may be related to the suppression of I to secondary to the increase in heart rate and/or to an increase in Ca 2+ current (I Ca ) due to an elevation of intracellular cyclic AMP concentration via inhibition of phosphodiesterase activity. This drug might have an anti‐VF potential in patients with Brugada syndrome.